Project Number 1R44AG076299-01 Agency/Funding Organization NIA Funding Year 2021 View Full Project Details for A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) c. ApoE, Lipids and Lipoprotein Receptors Researcher and Organization Principal Investigator JOHANSSON, JAN Principal Investigator First Name JAN Principal Investigator Last Name JOHANSSON Awardee Organization ARTERY THERAPEUTICS, INC. Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAS-19-316: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) FY Overall Cost $499,197 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M
